Fortified nutritional lubricating drops for dry eye disease
The invention describes ophthalmic pharmaceutical formulations comprising pharmaceutical ingredients to address DED symptoms. In one aspect of the invention, an ophthalmic pharmaceutical formulation comprises: 1) lubricity-promoting ingredient(s) such as those listed in the FDA over the counter (OTC) monograph for ophthalmics as demulcents and 2) surfactant(s) that solubilize lipids, assist in lubrication, and assist in easily spreading over hydrophobic surfaces; and/or 3) lipid and/or plant oil ingredient(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication; and/or 4) mucoadhesive and viscosity promoting polymer(s) that demonstrate shear thinning flow behavior. The pharmaceutical ingredients and osmoprotectant/tonicity ingredients are combined with ingredients that provide direct to the eye nutritional support that is comprehensive in nature. The total nutritional approach uses metabolically important tear fluid amino acids, vitamins, and both fatty acids/triglycerides and sugar molecules as energy sources. The invention results in both improved eye health and improved dry eye patient comfort.
1. An ophthalmic pharmaceutical formulation, comprising:
a. povidone with a concentration in the range of between about 1% and about 3% (w/w);
b. a mucoadhesive polymer selected from the group consisting of hyaluronic acid and salts thereof and carbomer, and combinations thereof;
c. poloxamer 407;
d. a surfactant selected from the group consisting of polyoxyl 35 castor oil and polyoxyl 40 hydrogenated castor oil, and combinations thereof;
e. ascorbic acid or a derivative thereof with an ascorbic acid equivalent concentration of about 0.03% (w/w) and trisodium citrate with a concentration of about 0.55% (w/w);
f. a tonicity agent selected from the group consisting of mannitol, sorbitol, and dextrose, and combinations thereof, in a total amount of up to about 5% (w/w); and
g. one or more osmoprotectants selected from the group consisting of proline, betaine, taurine, trehalose, and glutamic acid, and combinations thereof, in a total amount up to about 5% (w/w);
wherein the ophthalmic pharmaceutical formulation is preservative-free.
2. An ophthalmic pharmaceutical formulation composition comprising poloxamer 407, Hyaluronic acid or a salt thereof, and povidone, with a weight ratio of poloxamer 407 to hyaluronic acid or a salt thereof to povidone in the range between 1.0:0.05:0.625 and 1.0:0.05:0.75, wherein the ophthalmic pharmaceutical formulation is preservative-free.